Enzalutamide Interactions
Acetylsalicylic acid
No clinically significant drug interactions identified.
Alendronate
No clinically significant drug interactions identified.
Allopurinol
No clinically significant drug interactions identified.
Alprazolam
Caution - decreased level of alprazolam due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Amiodarone
Caution - decreased level of amiodarone due to 3A4/2C19 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Amitriptyline
No clinically significant drug interactions identified.
Amlodipine
Caution - decreased level of amlodipine due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Amoxicillin
No clinically significant drug interactions identified.
Amoxicillin/clavulanate
No clinically significant drug interactions identified.
Amphetamine
No clinically significant drug interactions identified.
Apixaban
Avoid combination - decreased level of apixaban due to 3A4 induction. Choose an alternative agent.
Aripiprazole (IM)
Avoid combinaton - decreased level of aripiprazole IM depot formulations due to 3A4 induction. Choose an alternative agent.
Aripiprazole (PO)
Caution - decreased level of aripiprazole due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required, depending on the indication. Consider choosing an alternative agent.
Atenolol
No clinically significant drug interactions identified.
Atomoxetine
No clinically significant drug interactions identified.
Atorvastatin
Caution - decreased level of atorvastatin due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Azithromycin
No clinically significant drug interactions identified.
Baclofen
No clinically significant drug interactions identified.
Bisoprolol
Caution - decreased level of bisoprolol due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Buprenorphine/naloxone
Caution - decreased level of buprenorphine/naloxone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Bupropion
No clinically significant drug interactions identified.
Buspirone
Avoid combination - decreased level of buspirone due to 3A4 induction. Choose an alternative agent.
Calcium
No clinically significant drug interactions identified.
Canagliflozin
No clinically significant drug interactions identified.
Candesartan
No clinically significant drug interactions identified.
Carbamazepine
Avoid combination - decreased level of enzalutamide due to 3A4 induction. Decreased level of carbamazepine due to 3A4 induction. Choose an alternative agent.
Carvedilol
Caution - decreased level of carvedilol due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Cephalexin
No clinically significant drug interactions identified.
Cetirizine
No clinically significant drug interactions identified.
Chlorthalidone
No clinically significant drug interactions identified.
Cholecalciferol
No clinically significant drug interactions identified.
Ciprofloxacin
No clinically significant drug interactions identified.
Citalopram
Caution - decreased level of citalopram due to 2C19/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Clarithromycin
Avoid combination - decreased level of clarithromycin due to 3A4 induction. Choose an alternative agent.
Clindamycin
Caution - decreased level of clindamycin due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Clomipramine
No clinically significant drug interactions identified.
Clonazepam
Caution - decreased level of clonazepam due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Clonidine
No clinically significant drug interactions identified.
Clopidogrel
Avoid combination - increased level of enzalutamide due to 2C8 inhibition. Choose an alternative agent.
Codeine
Caution - decreased level of codeine due to 3A4 induction. This results in an increased level of inactive metabolite "norcodeine", as opposed to its active metabolite of morphine through 2D6 metabolism. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Colchicine
Caution - increased level of colchicine due to P-gp inhibition, but decreased level of colchicine due to 3A4 induction. Unpredictable pharmacokinetics. Avoid use in patients with renal and/or hepatic impairment. Avoid use of extended release colchicine. Monitor for signs of toxicity, including increased bloodwork monitoring. Consider choosing an alternative agent.
Cyclobenzaprine
No clinically significant drug interactions identified.
Dabigatran
Caution - increased level of dabigatran due to P-gp inhibition. Monitor for signs of bleeding - a dose reduction may be required. Consider choosing an alternative agent.
Dapagliflozin
No clinically significant drug interactions identified.
Degarelix
No clinically significant drug interactions identified.
Denosumab
No clinically significant drug interactions identified.
Desipramine
No clinically significant drug interactions identified.
Desvenlafaxine
No clinically significant drug interactions identified.
Dexamethasone
Caution - decreased level of dexamethasone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required.
Dexlansoprazole
Caution - decreased level of dexlansoprazole due to 2C19 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Dextroamphetamine
No clinically significant drug interactions identified.
Diazepam
Caution - decreased level of diazepam due to 3A4/2C9/2C19 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Diclofenac
Caution - decreased level of diclofenac due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Digoxin
Avoid combination - increased level of digoxin due to P-gp inhibition. If concurrent use cannot be avoided, measure baseline serum digoxin level and monitor closely throughout treatment. Choose an alternative agent when possible.
Diltiazem
Avoid combination - decreased level of diltiazem due to 3A4 induction. Choose an alternative agent.
Dimenhydrinate
No clinically significant drug interactions identified.
Divalproex
No clinically significant drug interactions identified.
Docusate
No clinically significant drug interactions identified.
Domperidone
Caution - decreased level of domperidone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Donepezil
No clinically significant drug interactions identified.
Doxazosin
No clinically significant drug interactions identified.
Doxycycline
No clinically significant drug interactions identified.
Duloxetine
No clinically significant drug interactions identified.
Dutasteride
No clinically significant drug interactions identified.
Edoxaban
Caution - increased level of edoxaban due to P-gp inhibition. Monitor for signs of bleeding - a dose reduction may be required. Consider choosing an alternative agent.
Eletriptan
Caution - decreased level of eletriptan due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Empagliflozin
No clinically significant drug interactions identified.
Enalapril
No clinically significant drug interactions identified.
Escitalopram
Caution - decreased level of escitalopram due to 2C19/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Esomeprazole
No clinically significant drug interactions identified.
Ezetimibe
No clinically significant drug interactions identified.
Famotidine
No clinically significant drug interactions identified.
Fenofibrate
No clinically significant drug interactions identified.
Finasteride
No clinically significant drug interactions identified.
Fluconazole
No clinically significant drug interactions identified.
Fluoxetine
No clinically significant drug interactions identified.
Folic acid
No clinically significant drug interactions identified.
Fosfomycin
No clinically significant drug interactions identified.
Furosemide
No clinically significant drug interactions identified.
Gabapentin
No clinically significant drug interactions identified.
Galantamine
No clinically significant drug interactions identified.
Gliclazide
Caution - decreased level of gliclazide due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Glyburide
Caution - decreased level of glyburide due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Goserelin
No clinically significant drug interactions identified.
Guanfacine
Avoid combination - decreased level of guanfacine due to 3A4 induction. If concurrent use cannot be avoided, dose increase of guanfacine recommended. Choose an alternative agent.
Hydralazine
No clinically significant drug interactions identified.
Hydrochlorothiazide
No clinically significant drug interactions identified.
Hydromorphone
No clinically significant drug interactions identified.
Hydroxychloroquine
No clinically significant drug interactions identified.
Hydroxyzine
No clinically significant drug interactions identified.
Ibuprofen
No clinically significant drug interactions identified.
Indapamide
No clinically significant drug interactions identified.
Indomethacin
No clinically significant drug interactions identified.
Irbesartan
No clinically significant drug interactions identified.
Isotretinoin
No clinically significant drug interactions identified.
Itraconazole
Avoid combination - decreased level of itraconazole due to 3A4 induction. Choose an alternative agent.
Ketorolac
No clinically significant drug interactions identified.
Labetalol
No clinically significant drug interactions identified.
Lansoprazole
Caution - decreased level of lansoprazole due to 2C19/2C9/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Leuprolide
No clinically significant drug interactions identified.
